Changes in Beneficial Ownership · 4
uniQure N.V.
QURENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
edgar.xml
Filing details
- Report period
- 2026-06-30
- Issuer
- uniQure N.V.
- Issuer CIK
- 0001590560
- Trading symbol
- QURE
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Abi-Saab Walid
- Reporting owner CIK
- 0001985973
- Relationship
- Officer
- Officer title
- Chief Medical Officer
- Address
- C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, NETHERLANDS, P7, 1105BP
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | 2026-06-30 | M · Form 4[F1] | 10,000 | A | 5.59 | 178,235 | D |
| Ordinary Shares | 2026-06-30 | S · Form 4[F1] | 10,000 | D | 46.46[F2] | 168,235 | D |
| Ordinary Shares | 2026-06-30 | S · Form 4[F1] | 20,000 | D | 46.40[F3] | 148,235 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 5.59 | 2026-06-30 | M · Form 4[F1] | 10,000 | D | 0 | [F4] | 2034-03-01 | Ordinary Shares | 10,000 | 50,500 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.↩ 1↩ 2↩ 3↩ 4
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.↩ 1
- F3
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.↩ 1
- F4
- The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.↩ 1
Signature 1
- Signed
- /s/ Christian Klemt, Attorney-in-Fact
- Date
- 2026-07-02
Company context
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B - an historic achievement based on more than a decade of research and clinical development - represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com